Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Cytokinetics, Incorporated (CYTK) Guidance & Earnings Results

On 2026-02-24 Cytokinetics, Incorporated raised guidance: "2026 financial guidance provided; cash position ~$1.2B supports commercial…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CYTKCytokinetics, IncorporatedFollow CYTK — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
8.5B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
24 Feb 26Raised2026 financial guidance provided; cash position ~$1.2B supports commercial plans · full year

Cytokinetics, Incorporated — questions

What guidance did Cytokinetics, Incorporated give?
On 2026-02-24: "2026 financial guidance provided; cash position ~$1.2B supports commercial plans"
When does Cytokinetics, Incorporated report earnings?
Cytokinetics, Incorporated's next earnings report is expected on 2026-11-04.

Every figure on this page comes from Cytokinetics, Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.